Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2000

View Archived Issues

Eurand expands drug delivery capabilities

NIAID signs agreement with MVI/PATH for malaria vaccine research

Pig small intestine submucosa shows efficacy in wound healing

Aquila receives milestone payments under licensing agreements

NK1 receptor antagonist CP-99994 tested in ferret model of emesis

Oxford BioMedica to collaborate with AstraZeneca in drug discovery

Phase III results positive for memantine in AD

New Videx capsule formulation approved in France

Nastech's intranasal apomorphine compared to Viagra in phase II pilot trial

Magainin to begin clinical program for squalamine in genetic bone disorder

Buccal insulin/metformin combination therapy tested in type II diabetes

SciClone awarded grant to study novel immunomodulator in TB

Combidex NDA accepted for FDA review

PathoGenesis announces approval, distribution agreement for TOBI

Abbott launches new sedative for ICU use only

Use of FK-506 as topical analgesic disclosed

Cytotoxic artemisinin derivatives designed at Hong Kong U. of Science & Technology

U. of Texas designs new DNA-cleaving compounds

Antianginal agents with minimal arrhythmogenic potential developed at Lafon

Small-molecule transthyretin amyloid fibril inhibitors emerge from structure-based design program

Kinetix enters research collaboration with Dana-Farber Cancer Institute

Beijing-based researchers discover new antitumor indole derivatives

Allergan and Dura enter commercialization agreement for multiple products

Antiplatelet agents under study at Chinese centers

BIBN-4096BS: an extremely potent and selective CGRP antagonist for migraine

Second orphan drug designation granted for Maxamine

Selective 5-HT1D agonist L-775606 has reduced coronary vasoconstrictor effects vs. sumatriptan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...